Id: acc2013
Group: 2sens
Protein: JNK2
Gene Symbol: MAPK9
Protein Id: P45984
Protein Name: MK09_HUMAN
PTM: phosphorylation
Site: Thr183
Site Sequence: RTACTNFMMTPYVVTRYYRAP
Disease Category: Cancer
Disease: Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline: HuH-7
Disease Info:
Drug: resveratrol
Drug Info: "Resveratrol (Res) is a natural polyphenolic stilbene compound (C<sub>14</sub>H<sub>12</sub>O<sub>3</sub>) found in plants such as grapes, Polygonum cuspidatum, and peanuts, exhibiting antioxidant, anti-inflammatory, cardioprotective, and anticancer properties through mechanisms including SIRT1 activation and inhibition of cancer cell proliferation. ."
Effect: modulate
Effect Info: "Resveratrol inhibits the expression of u-PA and the metastasis of HCC cells, and suppresses the phosphorylation of JNK1/2."
Note:
Score: 4.0
Pubmed(PMID): 23437203
Sentence Index:
Sentence:

Sequence & Structure:

MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MAPK9 BENTAMAPIMOD c-Jun N-terminal kinase, JNK inhibitor 2 Completed endometriosis ClinicalTrials
MAPK9 TANZISERTIB c-Jun N-terminal kinase 2 inhibitor 2 Terminated idiopathic pulmonary fibrosis ClinicalTrials
MAPK9 TANZISERTIB c-Jun N-terminal kinase 2 inhibitor 2 Terminated lupus erythematosus ClinicalTrials
MAPK9 CC-401 c-Jun N-terminal kinase 2 inhibitor 1 Terminated myeloid leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
MAPK9-Thr183
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: